Gene-Editing Gear-Up, Harvard Expert Weighs Risks vs. Rewards in Trial's 55% LDL Slash
A gene-editing trial targeting high cholesterol showed promise, reducing LDL levels by up to 55%, but the safety and long-term effects remain concerns. The trial had a small sample size and did not have a control group.
From Reservist to Mass Shooter, Scientists Probe Alleged Lewiston Gunman's Brain for Clues to Rampage
Boston University's CTE Center is examining the brain of Robert Card, the suspected Lewiston shooter, to investigate potential links between his military service and mental health issues.
FDA Greenlights Revolutionary Sickle Cell Therapies from Vertex and CRISPR, Cracking $2 Million Cost Conundrum
The FDA approves a new gene therapy, Casgevy, for sickle cell disease in patients aged 12 and older, along with a second treatment, Lyfgenia, offering new options for this life-threatening disorder.
UMass Amherst Researchers Forge Grassroots Framework for Environmental Stewardship in Honduras
UMass Amherst researchers developed a grassroots ecological framework focusing on local engagement for environmental management, as detailed in PLOS ONE, and applied it to the Lake Yojoa watershed in Honduras.












